SUPREMES - Sunphenon in progressive forms of multiple sclerosis
SUPREMES - Sunphenon in progressive forms of multiple sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Sunphenon
What it measured
Main measures
Brain Parenchymal Fraction / atrophy after 36 months of treatment vs. placebo
Brain volume loss
Other measures (1)
T2 leasion, T1 hypotensive leasion, EDSS, changes in NAA/Cr quotient in spectroscopy, cognitive disorders and fatigue
Disability progressionMRI lesionsThinking and memoryFatigue
Who could take part
Progressive MS · EDSS 3 to 8
Show the full criteria
Inclusion criteria
Inclusion: age 18-65, primary or secondary progressive Multiple Sclerosis according to McDonald-criteria, EDSS 3-8, negative pregnancy test, use of highly effective methods of birth control in women with childbearing potential, informed consent, max. 4 cups of coffee and 2 cups of black tea daily, no consumption of grean tea or larger amounts of grapefruit juice, at least 30 days between the last relapse and screening Exclusion: relapsing remitting Multiple Sclerosis, clinical or laboratory findings of impaired liver function, psychiatric disorders, concomitant medication of hepatotoxic medication, any other relevant disorder
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate efficacy and safety of Sunphenon EGCg in progressive forms of multiple sclerosis after a 36 months treatment compared to the placebo-group, primary outcome criteria being reduction of Brain Parenchymal Fraction (atrophy)
Papers
Results
Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.Neurol Neuroimmunol Neuroinflamm · 2021
Loading reviews and guidelines…
History
Started
Aug 2008